Mark Kosko, MD
Ophthalmology · Jackson, MSNPI 1447578752
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,826 of the $26,810 with a category attached, or 66.5%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 71.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $22,234 and has fallen 96.3% since, to $822 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $147.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$19K
- AbbVie$2K
- Alcon$2K
- Ivantis, Inc$953
- Aerie Pharmaceuticals, Inc.$601
- Glaukos Corporation$478
- plus $2K from 14 others
What the payments were for
- Consulting fees$1,3005%
- Speaking & faculty fees$17,82666%
- Travel & lodging$9253%
- Food & beverage$6,71925%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $19,253 |
| AbbVie(2 entities) | 65 | $2,169 |
| Alcon | 42 | $1,832 |
| Ivantis, Inc | 6 | $953 |
| Aerie Pharmaceuticals, Inc. | 4 | $601 |
| Glaukos Corporation | 5 | $478 |
| Rxsight Inc | 11 | $408 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $275 |
| Amgen(2 entities) | 5 | $194 |
| Ellexiscience | 1 | $147 |
| Bausch & Lomb Americas Inc. | 2 | $144 |
| Sun Pharmaceutical Industries Inc. | 2 | $82 |
| Biotissue Holdings Inc. | 4 | $72 |
| Nova Eye, Inc. | 1 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Thea Pharma Inc. | 2 | $36 |
| Kala Pharmaceuticals, Inc. | 2 | $26 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Novartis | 1 | $12 |
| Iridex Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$18,821
- Hydrus$800
- Rocklatan$500
- XEN$274
- ARGOS$243
- AcrySof$233
- Tecnis IOL$212
- Clareon$143
- iDose$137
- AcrySof IQ PanOptix$128
- MIEBO$123
- XEN GLAUCOMA TREATMENT SYSTEM$120
- AcrySof IQ VIVITY$117
- TEPEZZA$112
- TOTAL30$108
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$101
How this compares
$26,810 in reported general payments places this provider in the 95th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 160 | $47,249 |
| LumiganBimatoprost | 81 | $33,555 |
| RestasisCyclosporine | 38 | $32,458 |
| Prednisolone Acetate | 553 | $19,141 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,023 | $16,907 |
| Latanoprost | 1,476 | $13,645 |
| Brinzolamide | 46 | $11,228 |
| AzoptBrinzolamide | 13 | $9,265 |
| VyzultaLatanoprostene Bunod | 21 | $8,748 |
| Brimonidine Tartrate | 499 | $7,494 |
| ProlensaBromfenac Sodium | 19 | $6,896 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 54 | $6,641 |
| Alphagan PBrimonidine Tartrate | 14 | $4,092 |
| Dorzolamide Hcl | 200 | $3,722 |
| Travoprost | 22 | $3,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis, Alphagan P | $2,169 | $117,354293 claims |
| AlconAzopt, Simbrinza | $1,832 | $12,18428 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $144 | $8,74821 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $19,253 | $6,89619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Jackson
- Heather HancockJackson$39K
- John ShippJackson$10K
- Kirk JeffreysJackson$9K
- Lee JonesJackson$8K
- Albert WilliamsJackson$6K
- Younghyun OhJackson$5K
- Farrah NewmanJackson$4K
- Taylor SmithJackson$4K
- Cassie ConfaitJackson$4K
- Curtis WhittingtonJackson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.